Spotlight on Prostate Cancer

Now Open: New Clinical Trial for Advanced Stage Prostate Cancer

A Phase 3 clinical trial comparing Ipilimumab to placebo is currently under way at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. The research study is designed to determine whether Ipilimumab is safe and effective for advanced prostate cancer when given after radiation therapy.

Ipilimumab, an investigational drug also known as MDX-010, has been shown to stimulate the body’s own immune system to fight prostate cancer. In previous studies, Ipilimumab was found to be effective in patients with metastatic prostate cancer that was resistant to hormonal therapy and in some cases, to chemotherapy.

Participants will be in the study for an initial 12 weeks. At that time, patients who are deriving benefit from the Ipilimumab may continue on study indefinitely.

To participate you must: 

• have a diagnosis of prostate cancer that has metastasized to the bone
• have previously undergone at least 1 chemotherapy regimen containing docetaxel (Taxotere)
• Our study physician, Dr. Charles Drake, and our research nurse Monica Taylor will discuss complete study criteria with you

Principal Investigator at Johns Hopkins:
Charles Drake, M.D., Ph.D.
Associate Professor of Medical Oncology, Immunology and Urology
Co-Director, The Johns Hopkins Prostate Cancer Multi-Disciplinary Clinic

To find out if you may be eligible to participate, please contact:
Monica Taylor, RN, BSN
Clinical Trials Research Nurse
Genitourinary Oncology
office: 410-614-9482
e-mail: mtaylo27@jhmi.edu
Protocol #: NA_00030529